Enrollment is now ongoing in a first-in-human clinical trial testing EPI-321, an epigenetic therapy designed to address FSHD.

Columnist Shalom Lin and his partner, Amanda — both disabled artists — find that their challenges are exactly what can drive ...

The FDA has granted breakthrough therapy designation to DYNE-251 for the treatment of DMD in patients amenable to exon 51 ...

A mouse model study of Precision BioSciences’ gene-editing therapy PBGENE-DMD found it produced long-term functional ...

Sarepta will soon resume shipping Elevidys for ambulatory Duchenne muscular dystrophy patients after a review of safety data ...

Share this article: An experimental gene editing therapy for Duchenne muscular dystrophy (DMD) being developed by Precision Biosciences has received orphan drug status from the U.S. Food and Drug ...

View this post on Instagram Day 4 of 30 Days of MD Topic: Self Confidence and DMD This is Milan Patel’s story: Growing up with Duchenne Muscular Dystrophy, I was often self-conscious, especially after ...

View this post on Instagram Day 2 of 30 Days of MD Topic: Being a Teenager This is Kimberly Mullis’ story: Hey fam, I’m Kimmy!! (The one in the middle:) I have SMA II, and am truly living my best ...

View this post on Instagram Day 8 of #30daysofMD - Casey Duffield’s Story Accommodations and MD I think the word accommodation needs some accommodating. As someone who looks relatively healthy and ...

View this post on Instagram Day 28 of 30 Days of MD Topic: Genetics and Gardening This is @cocohollywood’s story: Lurking in my mom’s genetics is FSH muscular dystrophy (facioscapulohumeral muscular ...

View this post on Instagram Day 8 of 30 Days of MD Topic: Poem About MD This is @writingpoemsinthedark’s story: Simply put, I write to connect. Poetry allows me to address and work through topics that ...

View this post on Instagram Day 10 of #30daysofMD This is @faithabovemyability story: Topic: Faith, disability, and advocacy I was born with a type of muscular dystrophy, but 30.5 years later, I’m ...